You are here: Industry Insights > Blueprint Medicines

News List

Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines pharmaceutical-technolog
July 15, 2020
Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.
Blueprint Medicines Receives CRL for Avapritinib americanpharmaceuticalreview
May 20, 2020
Blueprint Medicines announced the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of avapritinib.
Blueprint Medicines Announces FDA Acceptance of NDA for Avapritinib americanpharmaceuticalreview
August 09, 2019
Blueprint Medicines announced the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for avapritinib for the treatment of adult patients with ...
Blueprint Medicines Announces EMA Validation for Avapritinib americanpharmaceuticalreview
July 22, 2019
Blueprint Medicines announced the European Medicines Agency (EMA) has validated the company's Marketing Authorization Application (MAA) for avapritinib for the treatment of adult patients with PDGFRα D842V mutant gastrointestinal stromal tumors (GIST) ...
Blueprint Medicines Submits NDA for Avapritinib americanpharmaceuticalreview
June 20, 2019
Blueprint Medicines has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avapritinib for the treatment of adult patients with PDGFRA Exon 18 mutant gastrointestinal stromal tumors (GIST) ...
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress firstwordpharma
March 28, 2019
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to expedite development of avapritinib, BLU-667 and BLU-782 based on recent c
Blueprint’s Tagrisso combination shows early promise in NSCLC fiercebiotech
September 28, 2018
Based on these data, Blueprint is looking into testing the combination in more patients with the same treatment-resistant EGFR-mutant cancer.
Blueprint Medicines' RET inhibitor BLU-667 shows "broad anti-tumour" activity in early-stage study firstwordpharma
April 16, 2018
Blueprint Medicines reported Sunday data from an early-stage study of BLU-667 in patients with RET-altered solid tumours, with the experimental drug showing "broad anti-tumour" activity.
Thermo Fisher signs agreement with Blueprint Medicines biospectrumasia
November 03, 2017
BLU-667 is currently being evaluated by Blueprint Medicines in a Phase 1 clinical trial for the treatment of patients with RET-driven NSCLC, thyroid cancer and other advanced solid tumors.